Immunosenescence and vaccine efficacy revealed by immunometabolic analysis of SARS-CoV-2-specific cells in multiple sclerosis patients
© 2024. The Author(s)..
Disease-modifying therapies (DMT) administered to patients with multiple sclerosis (MS) can influence immune responses to SARS-CoV-2 and vaccine efficacy. However, data on the detailed phenotypic, functional and metabolic characteristics of antigen (Ag)-specific cells following the third dose of mRNA vaccine remain scarce. Here, using flow cytometry and 45-parameter mass cytometry, we broadly investigate the phenotype, function and the single-cell metabolic profile of SARS-CoV-2-specific T and B cells up to 8 months after the third dose of mRNA vaccine in a cohort of 94 patients with MS treated with different DMT, including cladribine, dimethyl fumarate, fingolimod, interferon, natalizumab, teriflunomide, rituximab or ocrelizumab. Almost all patients display functional immune response to SARS-CoV-2. Different metabolic profiles characterize antigen-specific-T and -B cell response in fingolimod- and natalizumab-treated patients, whose immune response differs from all the other MS treatments.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Nature communications - 15(2024), 1 vom: 29. März, Seite 2752 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
De Biasi, Sara [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Fingolimod Hydrochloride |
|---|
| Anmerkungen: |
Date Completed 01.04.2024 Date Revised 26.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41467-024-47013-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM37043000X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM37043000X | ||
| 003 | DE-627 | ||
| 005 | 20240426234051.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240331s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41467-024-47013-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1388.xml |
| 035 | |a (DE-627)NLM37043000X | ||
| 035 | |a (NLM)38553477 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a De Biasi, Sara |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunosenescence and vaccine efficacy revealed by immunometabolic analysis of SARS-CoV-2-specific cells in multiple sclerosis patients |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.04.2024 | ||
| 500 | |a Date Revised 26.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a Disease-modifying therapies (DMT) administered to patients with multiple sclerosis (MS) can influence immune responses to SARS-CoV-2 and vaccine efficacy. However, data on the detailed phenotypic, functional and metabolic characteristics of antigen (Ag)-specific cells following the third dose of mRNA vaccine remain scarce. Here, using flow cytometry and 45-parameter mass cytometry, we broadly investigate the phenotype, function and the single-cell metabolic profile of SARS-CoV-2-specific T and B cells up to 8 months after the third dose of mRNA vaccine in a cohort of 94 patients with MS treated with different DMT, including cladribine, dimethyl fumarate, fingolimod, interferon, natalizumab, teriflunomide, rituximab or ocrelizumab. Almost all patients display functional immune response to SARS-CoV-2. Different metabolic profiles characterize antigen-specific-T and -B cell response in fingolimod- and natalizumab-treated patients, whose immune response differs from all the other MS treatments | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Fingolimod Hydrochloride |2 NLM | |
| 650 | 7 | |a G926EC510T |2 NLM | |
| 650 | 7 | |a Natalizumab |2 NLM | |
| 650 | 7 | |a mRNA Vaccines |2 NLM | |
| 700 | 1 | |a Lo Tartaro, Domenico |e verfasserin |4 aut | |
| 700 | 1 | |a Neroni, Anita |e verfasserin |4 aut | |
| 700 | 1 | |a Rau, Moritz |e verfasserin |4 aut | |
| 700 | 1 | |a Paschalidis, Nikolaos |e verfasserin |4 aut | |
| 700 | 1 | |a Borella, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Santacroce, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Paolini, Annamaria |e verfasserin |4 aut | |
| 700 | 1 | |a Gibellini, Lara |e verfasserin |4 aut | |
| 700 | 1 | |a Ciobanu, Alin Liviu |e verfasserin |4 aut | |
| 700 | 1 | |a Cuccorese, Michela |e verfasserin |4 aut | |
| 700 | 1 | |a Trenti, Tommaso |e verfasserin |4 aut | |
| 700 | 1 | |a Rubio, Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Vitetta, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Cardi, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Argüello, Rafael José |e verfasserin |4 aut | |
| 700 | 1 | |a Ferraro, Diana |e verfasserin |4 aut | |
| 700 | 1 | |a Cossarizza, Andrea |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 15(2024), 1 vom: 29. März, Seite 2752 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g number:1 |g day:29 |g month:03 |g pages:2752 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-024-47013-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |e 1 |b 29 |c 03 |h 2752 | ||